AMGN Insider Trading

Insider Ownership Percentage: 0.69%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $21,307,146.27

Amgen Insider Trading History Chart

This chart shows the insider buying and selling history at Amgen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$21MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M$0$20MTotal Insider BuyingTotal Insider Selling

Amgen Share Price & Price History

Current Price: $306.95
Price Change: Price Increase of +1.18 (0.39%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for AMGN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$305.77Closing price on 03/27/25:

SEC Filings (Institutional Ownership Changes) for Amgen (NASDAQ:AMGN)

76.50% of Amgen stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at AMGN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$12Bbought$7.86BsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50B$0$50BTotal InflowsTotal Outflows
Amgen logo
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Read More on Amgen

Today's Range

Now: $306.95
Low: $304.72
High: $308.17

50 Day Range

MA: $300.39
Low: $272.11
High: $327.36

52 Week Range

Now: $306.95
Low: $253.30
High: $346.85

Volume

1,768,376 shs

Average Volume

2,701,061 shs

Market Capitalization

$164.90 billion

P/E Ratio

40.66

Dividend Yield

3.10%

Beta

0.53

Who are the company insiders with the largest holdings of Amgen?

Amgen's top insider investors include:
  1. Amgen Inc (Major Shareholder)
  2. David M Reese (EVP)
  3. Murdo Gordon (EVP)
  4. Jonathan P Graham (EVP)
  5. Nancy A Grygiel (SVP)
Learn More about top insider investors at Amgen.

Who are the major institutional investors of Amgen?

Amgen's top institutional investors include:
  1. Vanguard Group Inc. — 9.81%
  2. Charles Schwab Investment Management Inc. — 2.46%
  3. Primecap Management Co. CA — 2.42%
  4. Geode Capital Management LLC — 2.32%
  5. Capital International Investors — 2.27%
  6. Capital World Investors — 1.21%
Learn More about top institutional investors of Amgen stock.

Which institutional investors are selling Amgen stock?

Within the previous quarter, AMGN stock was sold by these institutional investors:
  1. International Assets Investment Management LLC
  2. Janus Henderson Group PLC
  3. Price T Rowe Associates Inc. MD
  4. Nuveen Asset Management LLC
  5. Primecap Management Co. CA
  6. Legal & General Group Plc
  7. Assenagon Asset Management S.A.
  8. Voya Investment Management LLC
In the previous year, company insiders that have sold Amgen company stock include:
  1. Amgen Inc (Major Shareholder)
  2. David M Reese (EVP)
  3. Murdo Gordon (EVP)
  4. Jonathan P Graham (EVP)
Learn More investors selling Amgen stock.

Which institutional investors are buying Amgen stock?

During the last quarter, AMGN stock was bought by institutional investors including:
  1. Capital World Investors
  2. Norges Bank
  3. Capital International Investors
  4. Charles Schwab Investment Management Inc.
  5. Raymond James Financial Inc.
  6. Franklin Resources Inc.
  7. Northern Trust Corp
  8. Capital Research Global Investors